References
- Gournay M, Paineau M, Archambeau J, Pedeux R. Regulat-INGs in tumors and diseases: focus on ncRNAs. Cancer Lett. 2019;447:66–74.
- Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127(3):761–771. doi:https://doi.org/10.1172/JCI84424
- Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51. doi:https://doi.org/10.1016/j.cell.2018.03.006
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:https://doi.org/10.1016/s0092-8674(04)00045-5
- Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8(2):93–103. doi:https://doi.org/10.1038/nrg1990
- Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087–2092. doi:https://doi.org/10.1111/j.1349-7006.2010.01650.x
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–906. doi:https://doi.org/10.1038/35002607
- Beg MS, Brenner AJ, Sachdev J, Borad M, Kang Y-K, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180–188. doi:https://doi.org/10.1007/s10637-016-0407-y
- Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183(3):428–444. doi:https://doi.org/10.1111/bjh.15547
- Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med. 2011;15(1):14–23. doi:https://doi.org/10.1111/j.1582-4934.2010.01219.x
- Tanzer A, Amemiya CT, Kim CB, Stadler PF. Evolution of microRNAs located within Hox gene clusters. J Exp Zool B Mol Dev Evol. 2005;304(1):75–85. doi:https://doi.org/10.1002/jez.b.21021
- Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009;113(14):3314–3322. doi:https://doi.org/10.1182/blood-2008-04-154310
- Wang S-Y, Chen C-L, Hu Y-C, Chi Y, Huang Y-H, Su C-W, Jeng W-J, Liang Y-J, Wu J-C. High expression of MicroRNA-196a is associated with progression of hepatocellular carcinoma in younger patients. Cancers. 2019;11(10):1549. doi:https://doi.org/10.3390/cancers11101549
- Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010;16:4289–4297. doi:https://doi.org/10.1158/1078-0432.CCR-10-0207
- Zhao X, Zhang W, Ji W. miR-196b is a prognostic factor of human laryngeal squamous cell carcinoma and promotes tumor progression by targeting SOCS2. Biochem Biophys Res Commun. 2018;501(2):584–592. doi:https://doi.org/10.1016/j.bbrc.2018.05.052
- Xu L, Guo Y, Yan W, Cen J, Niu Y, Yan Q, et al. High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome. EXCLI J. 2017;16:197.
- Ge J, Chen Z, Li R, Lu T, Xiao G. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int. 2014;14:128.
- Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR, Castellano L. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther. 2011;11(12):1837–1842. doi:https://doi.org/10.1586/era.11.184
- Yu Q, Xu C, Yuan W, Wang C, Zhao P, Chen L, Ma J. Evaluation of plasma MicroRNAs as diagnostic and prognostic biomarkers in pancreatic adenocarcinoma: miR-196a and miR-210 could be negative and positive prognostic markers. Respectively. 2017;2017:1–10. doi:https://doi.org/10.1155/2017/6495867
- Kanno S, Nosho K, Ishigami K, Yamamoto I, Koide H, Kurihara H, Mitsuhashi K, Shitani M, Motoya M, Sasaki S, et al. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Carcinogenesis. 2017;38:425–431. doi:https://doi.org/10.1093/carcin/bgx013
- Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl A-M, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, et al. miR-196b-5p regulates colorectal cancer cell migration and metastases through interaction with HOXB7 and GALNT5. Clin Cancer Res. 2017;23(17):5255–5266. doi:https://doi.org/10.1158/1078-0432.CCR-17-0023
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–2012. doi:https://doi.org/10.1001/jama.283.15.2008
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemio. 2009;62(10):e1-e34.
- Parmar MKB, Torri V, L S. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834. doi:https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
- Williamson PR, Smith CT, Hutton JL, M AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–3351. doi:https://doi.org/10.1002/sim.1303
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:https://doi.org/10.1186/1745-6215-8-16
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:https://doi.org/10.1007/s10654-010-9491-z
- Higgins JPT, T SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:https://doi.org/10.1002/sim.1186
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:https://doi.org/10.1136/bmj.327.7414.557
- Mantel NJ, Haenszel W. Statistical aspects of the analysis of data from retrospective studies. J Natl Cancer Inst. 1959;22(4):719–748.
- Dersimonian R, Nan L. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7(3):177–188. doi:https://doi.org/10.1016/0197-2456(86)90046-2
- Begg CB, Mazumdar MJB. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. doi:https://doi.org/10.2307/2533446
- Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y, et al. Erratum to: detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011;56(3):921. doi:https://doi.org/10.1007/s10620-010-1410-3
- Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu C-G, Bhatt D, Taccioli C, Croce CM, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901–1908. doi:https://doi.org/10.1001/jama.297.17.1901
- Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y, et al. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis. 2019;10:333.
- Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F, Zhang W, Zhang J, Tao T, You Y, et al. Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS One. 2012;7(6):e38096. doi:https://doi.org/10.1371/journal.pone.0038096
- Yang G, Han D, Chen X, Zhang D, Wang L, Shi C, Zhang W, Li C, Chen X, Liu H, et al. MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IκBα both in vitro and in vivo. Neuro Oncol. 2014;16(5):652–661. doi:https://doi.org/10.1093/neuonc/not307
- Zhao S, Yang G, Mu Y, Han D, Shi C, Chen X, Deng Y, Zhang D, Wang L, Liu Y, et al. MiR-106a is an independent prognostic marker in patients with glioblastoma. Neuro Oncol. 2013;15:707–717. doi:https://doi.org/10.1093/neuonc/not001
- Luo M, Sun G, Sun J-w. MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17. Auris Nasus Larynx. 2019;46(4):583–592. doi:https://doi.org/10.1016/j.anl.2018.10.020
- Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia. 2014;28(4):804–812. doi:https://doi.org/10.1038/leu.2013.281
- Zhang JYu, Liu WE, Du J, Jin YJin, Zhao MLei, Li LJie, Wang Y. Prognostic impact of miR-196a/b expression in adult acute myeloid leukaemia: a single-centre, retrospective cohort study. J Int Med Res. 2018;46(9):3675–3683. doi:https://doi.org/10.1177/0300060518777399
- Fan Y, Fan J, Huang L, Ye M, Huang J. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma. Int J Clin Exp Pathol. 2015;8:4132–4137.
- Liu P, F X, M CF. Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer. Genet Mol Res. 2015;14(4):17995–18002. doi:https://doi.org/10.4238/2015.December.22.25
- Hou T, Ou J, Zhao X, Huang X, Huang Y, Zhang Y. MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer. 2014;110(5):1260–1268. doi:https://doi.org/10.1038/bjc.2013.829
- Mu Y-P, Tang S, Sun W-J, Gao W-M, Wang M, Su X-L. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer. Asian Pac J Cancer Prev. 2014;15(20):8893–8900. doi:https://doi.org/10.7314/APJCP.2014.15.20.8893
- Lim JY, Yoon SO, Seol S-Y, Hong SW, Kim JW, Choi SH. Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol. 2013;19(41):7078–7088.
- Tsai M-M, Wang C-S, Tsai C-Y, Chen C-Y, Chi H-C, Tseng Y-H, Chung P-J, Lin Y-H, Chung I-H, Chen C-Y, et al. MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. Cancer Lett. 2014;351(2):222–231. doi:https://doi.org/10.1016/j.canlet.2014.06.004
- Tsai M-M, Wang C-S, Tsai C-Y, Huang C-G, Lee K-F, Huang H-W, Lin Y-H, Chi H-C, Kuo L-M, Lu P-H, et al. Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer. Eur J Cancer. 2016;64:137–148. doi:https://doi.org/10.1016/j.ejca.2016.05.007
- Sun M, Liu X-h, Li J-h, Yang J-s, Zhang E-b, Yin D-d, Liu Z-l, Zhou J, Ding Y, Li S-q, et al. MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther. 2012;11(4):842–852. doi:https://doi.org/10.1158/1535-7163.MCT-11-1015
- Li CY, Liang GY, Yao WZ, Sui J, Pu Y-P. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression. Clin Transl Oncol. 2016;19:1–11.
- Zhang C, Yao C, Li H, Wang G, He X. Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas. Int J Mol Sci. 2014;15(4):6544–6555. doi:https://doi.org/10.3390/ijms15046544
- Han J. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016–3027. doi:https://doi.org/10.1101/gad.1262504
- Kim NV. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376–385. doi:https://doi.org/10.1038/nrm1644
- Liu X-h, Lu K-h, Wang K-m, Sun M, Zhang E-b, Yang J-s, Yin D-d, Liu Z-l, Zhou J, Liu Z-j, et al. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer. 2012;12:348. doi:https://doi.org/10.1186/1471-2407-12-348
- Milevskiy MJG, Gujral U, Del Lama Marques C, Stone A, Northwood K, Burke LJ, Gee JMW, Nephew K, Clark S, Brown MA, et al. MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER + breast cancer. Br J Cancer. 2019;120(6):621–632. doi:https://doi.org/10.1038/s41416-019-0395-8
- Zeller KI, Zhao X, Lee CWH, Chiu KP, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA. 2006;103(47):17834–17839. doi:https://doi.org/10.1073/pnas.0604129103
- De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM, Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene. 2009;28(11):1432–1442. doi:https://doi.org/10.1038/onc.2008.495
- Fantini S, Salsi V, Vitobello A, Rijli FM, Zappavigna V. MicroRNA-196b is transcribed from an autonomous promoter and is directly regulated by Cdx2 and by posterior Hox proteins during embryogenesis. Biochim Biophys Acta. 2015;1849(8):1066–1080. doi:https://doi.org/10.1016/j.bbagrm.2015.06.014
- Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, Stebbing J, Giamas G. LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Lett. 2016;372(1):137–146. doi:https://doi.org/10.1016/j.canlet.2015.12.026
- Ye Y, Yang S, Han Y, Sun J, Xv L, Wu L, Wang Y, Ming L. Linc00472 suppresses proliferation and promotes apoptosis through elevating PDCD4 expression by sponging miR-196a in colorectal cancer. Aging (Albany NY)). 2018;10(6):1523–1533. doi:https://doi.org/10.18632/aging.101488
- Xu L, Hou TJ, Yang P. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a. Eur Rev Med Pharmacol Sci. 2019;23(15):6505–6515. doi:https://doi.org/10.26355/eurrev_201908_18534
- Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol. 2017;39(7):1010428317711315. doi:https://doi.org/10.1177/1010428317711315
- Zhao H, Yu H, Zheng J, Ning N, Tang F, Yang Y, Wang Y. Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5. Gynecol Oncol. 2018;151(2):345–355. doi:https://doi.org/10.1016/j.ygyno.2018.08.032
- Zhong F, Zhang W, Cao Y, Wen Q, Cao Y, Lou B, Li J, Shi W, Liu Y, Luo R, et al. LncRNA NEAT1 promotes colorectal cancer cell proliferation and migration via regulating glial cell-derived neurotrophic factor by sponging miR-196a-5p. Acta Biochim Biophys Sin (Shanghai)). 2018;50(12):1190–1199. doi:https://doi.org/10.1093/abbs/gmy130
- Wang H-L, Zhou R, Liu J, Chang Y, Liu S, Wang X-B, Huang M-F, Zhao Q. MicroRNA-196b inhibits late apoptosis of pancreatic cancer cells by targeting CADM1. Sci Rep. 2017;7(1):11467. doi:https://doi.org/10.1038/s41598-017-11248-3
- Shi X-H, Li X, Zhang H, He R-Z, Zhao Y, Zhou M, Pan S-T, Zhao C-L, Feng Y-C, Wang M, et al. A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci Rep. 2018;8(1):1–10. doi:https://doi.org/10.1038/s41598-018-22493-5
- Chong GO, Jeon H-S, Han HS, Son JW, Lee YH, Hong DG, Park HJ, Lee YS, Cho YL. Overexpression of microRNA-196b accelerates invasiveness of cancer cells in recurrent epithelial ovarian cancer through regulation of homeobox A9. Cancer Genomics Proteomics. 2017;14(2):137–141. doi:https://doi.org/10.21873/cgp.20026
- Bai X, Meng L, Sun H, Li Z, Zhang X, Hua S. MicroRNA-196b inhibits cell growth and metastasis of lung cancer cells by targeting Runx2. Cell Physiol Biochem. 2017;43(2):757–767. doi:https://doi.org/10.1159/000481559
- Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y, Liang Y, Cao L, Li X, Li R, et al. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget. 2017;8(30):49807–49823. doi:https://doi.org/10.18632/oncotarget.17971
- Han Q, Zhou C, Liu F, Xu G, Zheng R, Zhang X. MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. Oncol Rep. 2015;34(2):877–883. doi:https://doi.org/10.3892/or.2015.4049
- Chen Y, Huang S, Wu B, Fang J, W S. Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression. Oncotarget J. 2017;8(30):49110–49122.
- Li H-L, Xie S-P, Yang Y-L, Cheng Y-X, Zhang Y, Wang J, Wang Y, Liu D-L, Chen Z-F, Zhou Y-N, et al. Clinical significance of upregulation of mir-196a-5p in gastric cancer and enriched KEGG pathway analysis of target genes. Asian Pac J Cancer Prev. 2015;16(5):1781–1787. doi:https://doi.org/10.7314/APJCP.2015.16.5.1781
- Wu Y, Zhou T, Tang Q, Xiao J. HOXA5 inhibits tumor growth of gastric cancer under the regulation of microRNA-196a. Gene. 2019;681:62–68. doi:https://doi.org/10.1016/j.gene.2018.09.051
- Shang Y, Wang LQ, Guo QY, Shi TL. MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway. Int J Clin Exp Pathol. 2015;8(3):2461–2472.
- Chen X, Du P, She J, Cao L, Li Y, Xia H. Loss of ZG16 is regulated by miR-196a and contributes to stemness and progression of colorectal cancer. Oncotarget. 2016;7(52):86695–86703. doi:https://doi.org/10.18632/oncotarget.13435
- Xin H, Wang C, Liu Z. miR-196a-5p promotes metastasis of colorectal cancer via targeting IκBα. BMC Cancer. 2019;19(1):30. doi:https://doi.org/10.1186/s12885-018-5245-1
- Yang J-p, Yang J-k, Li C, Cui Z-q, Liu H-j, Sun X-f, Geng S-m, Lu S-k, Song J, Guo C-y, et al. Downregulation of ZMYND11 induced by miR-196a-5p promotes the progression and growth of GBM. Biochem Biophys Res Commun. 2017;494(3–4):674–680. doi:https://doi.org/10.1016/j.bbrc.2017.10.098
- Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667–6678. doi:https://doi.org/10.1038/onc.2008.256
- Bai M, Dong Y, Zhou C, Sun X, Ma J, Han S. Effect of miR-196a inhibition on esophageal cancer growth in vitro. Anti-Cancer Drugs. 2020;31(2):169–176. doi:https://doi.org/10.1097/CAD.0000000000000823
- Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, Yao H, Zhang S. MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PLoS One. 2014;9(2):e87897. doi:https://doi.org/10.1371/journal.pone.0087897
- Zhang J, Zheng F, Yu G, Yin Y, Lu Q. miR-196a targets netrin 4 and regulates cell proliferation and migration of cervical cancer cells. Biochem Biophys Res Commun. 2013;440(4):582–588. doi:https://doi.org/10.1016/j.bbrc.2013.09.142
- Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12. doi:https://doi.org/10.1186/s13059-018-1604-0
- Suh Y-E, Raulf N, Gäken J, Lawler K, Urbano TG, Bullenkamp J, Gobeil S, Huot J, Odell E, Tavassoli M, et al. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. Int J Cancer. 2015;137(5):1021–1034. doi:https://doi.org/10.1002/ijc.29397
- Ma R, Zheng G, Shao C, Liu J, Lv H, Zhang G. Downregulation of miR-196b promotes glioma cell sensitivity to temozolomide chemotherapy and radiotherapy. Ann Clin Lab Sci. 2018;48(6):719–725.
- Shen YN, Bae IS, Park GH, Choi HS, Lee KH, Kim SH. MicroRNA-196b enhances the radiosensitivity of SNU-638 gastric cancer cells by targeting RAD23B. Biomed Pharmacother. 2018;105:362–369. doi:https://doi.org/10.1016/j.biopha.2018.05.111
- Clark PM, Chitnis N, Shieh M, Kamoun M, Monos D. Novel and haplotype specific MicroRNAs encoded by the major histocompatibility complex. Sci Rep. 2018;8:3832.
- Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6(17):1967–1984. doi:https://doi.org/10.4155/fmc.14.116
- Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 2015;16(2):2810–2823. doi:https://doi.org/10.3390/ijms16022810
- Islam W, Adnan M, Huang Z, Lu G-d, C HYH. Small RNAs from seed to mature plant. Crit Rev Plant Sci. 2019;38:1–23.
- Cai X, Liu X, Lu N, Xiao M, Li Z. Prognostic value of microRNA-196a in Asian cancer patients: a meta-analysis. Clin Lab. 2016;62(11):2257–2265. doi:https://doi.org/10.7754/Clin.Lab.2016.160425
- Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget. 2010;1(3):224–227. doi:https://doi.org/10.18632/oncotarget.129
- Shindo Y, Hazama S, Nakamura Y, Inoue Y, Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno T, et al. miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncol Lett. 2017;14(2):1355–1362. doi:https://doi.org/10.3892/ol.2017.6303
- Hao Y, Wang J, Zhao L. The effect and mechanism of miR196a in HepG2 cell. Biomed Pharmacother. 2015;72:1–5. doi:https://doi.org/10.1016/j.biopha.2014.10.032
- Yang L, Peng F, Qin J, Zhou H, Wang B. Downregulation of microRNA-196a inhibits human liver cancer cell proliferation and invasion by targeting FOXO1. Oncol Rep. 2017;38(4):2148–2154. doi:https://doi.org/10.3892/or.2017.5873
- Yu Z, Lin X, Tian M, Chang W. MicroRNA-196b promotes cell migration and invasion by targeting FOXP2 in hepatocellular carcinoma. Oncol Rep. 2018;39:731–738.
- Rebucci M, Sermeus A, Leonard E, Delaive E, Dieu M, Fransolet M, Arnould T, Michiels C. miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Mol Cancer. 2015;14:79. doi:https://doi.org/10.1186/s12943-015-0349-6